Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Connect Biopharma Holdings ( (CNTB) ) has issued an announcement.
Between September 2024 and September 2025, Barry D. Quart, CEO and Director of Connect Biopharma Holdings, and David Szekeres, President of the Company, purchased a significant number of shares, totaling 224,034 and 215,739 respectively. These transactions were conducted in compliance with the company’s Insider Trading Compliance Policy, indicating a strong vote of confidence in the company’s future prospects by its top executives.
The most recent analyst rating on (CNTB) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Connect Biopharma Holdings stock, see the CNTB Stock Forecast page.
Spark’s Take on CNTB Stock
According to Spark, TipRanks’ AI Analyst, CNTB is a Neutral.
Connect Biopharma Holdings’ overall score reflects the challenges of unprofitability and negative cash flow despite recent revenue growth and a strong balance sheet. Technical indicators suggest a bearish trend, while the valuation highlights the risks typical of early-stage biotech firms. However, the positive corporate event regarding FDA support for Phase 2 trials offers a promising growth opportunity in the pipeline, improving the outlook.
To see Spark’s full report on CNTB stock, click here.
More about Connect Biopharma Holdings
Average Trading Volume: 184,405
Technical Sentiment Signal: Buy
For an in-depth examination of CNTB stock, go to TipRanks’ Overview page.